---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031482"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:46:21.394861+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024

## Summary
- Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.
- Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.
- Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).
- ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024.

## SEC filing metadata
- accession: 0000950170-24-031482
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/0000950170-24-031482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/elvn-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031482
- JSON: https://secwatch.observer/filing/0000950170-24-031482.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031482.txt

## Key facts
- Earnings Releases
  Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: net loss of $19.4 million for the fourth quarter of 2023
  - Result: reported results
  source text: Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/0000950170-24-031482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.